Navigation Links
MS drug shows promise for preventing heart failure
Date:7/16/2013

A drug already approved to treat multiple sclerosis may also hold promise for treating cardiac hypertrophy, or thickening of the cardiac muscle--a disorder that often leads to heart failure, researchers at the University of Illinois at Chicago College of Medicine report.

The findings are published in the July 16 issue of Circulation: Heart Failure.

Cardiac hypertrophy is a slow thickening of the heart muscle that shrinks the interior volume of the heart, forcing the organ to work harder to pump a diminishing volume of blood.

"There comes a day when the heart just can't keep up any more, and it fails," says R. John Solaro, UIC distinguished university professor and head of physiology and biophysics.

Cardiac hypertrophy, which afflicts one in 500 people, can be caused by high blood pressure or inherited through genes that control contraction of the heart.

Solaro and his colleagues believe that if the thickening of the heart muscle could be slowed, or maybe even reversed, heart failure could be prevented.

Solaro and his UIC colleague Yunbo Ke, research assistant professor of physiology and biophysics, were interested in a chemical derived from a fungus used in traditional Chinese medicine as an eternal-youth nostrum. That compound, designated FTY-720, has been developed into a drug to treat multiple sclerosis and is a chemical cousin to the drug most widely used to suppress the immune system and prevent organ rejection in transplant patients.

The substance, Solaro said, "mimics certain lipids in the body that play a role in the development of cardiac hypertrophy."

Using an experimental mouse model of cardiac hypertrophy, Solaro and his team found that FTY-720 significantly reduced heart mass; lessened fibrosis, or stiffening of the heart muscle; and improved overall cardiac function in the mice that received the drug.

The researchers also showed that the drug inhibits expression of several genes involved in cardiac hypertrophy.

"We saw that FTY-720 blocked the activity of a protein we know is involved in causing heart-cell thickening," said Solaro. When that protein is blocked, he said, collagen and other proteins involved in heart-cell thickening are also down-regulated.

Collagen, a fibrous protein found between heart cells, causes the heart muscle to become stiff. Collagen is often overabundant in people with cardiac hypertrophy.

"When the heart muscle is stiff, it actually takes effort to relax the heart and allow blood to flow into the ventricles, so this is another way this disease causes the heart to work harder than it should have to," Solaro said.

"FTY-720 is a potential therapy to treat this disease and prevent heart failure for people where the disease is acquired through high blood pressure, and possibly inherited hypertrophy as well," he said.


'/>"/>

Contact: Sharon Parmet
sparmet@uic.edu
312-413-2695
University of Illinois at Chicago
Source:Eurekalert

Related biology news :

1. Genetic survey of endangered Antarctic blue whales shows surprising diversity
2. University of Houston study shows BP oil spill hurt marshes, but recovery possible
3. Weakness can be an advantage in surviving deadly parasites, a new study shows
4. Study shows unified process of evolution in bacteria and sexual eukaryotes
5. Sexual reproduction brings long-term benefits, study shows
6. UCSB study shows forest insects and diseases arrive in US via imported plants
7. Study shows botanical formula fights prostate cancer
8. Transcatheter aortic valve implantation shows promise in patients with severe aortic stenosis
9. Buy coal? New analysis shows purchasing fossil fuel deposits best way to fight climate change
10. Global Surgical Devices Market Growth Driven by Improving Standards of Living and Longer Life Expectancies, Research Shows
11. CU research shows warming climate threatens ecology at mountain research site west of Boulder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/11/2017)... Fla. , April 11, 2017 ... and secure authentication solutions, today announced that it ... Intelligence Advanced Research Projects Activity (IARPA) to develop ... Thor program. "Innovation has been a ... IARPA,s Thor program will allow us to innovate ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
(Date:3/30/2017)... 30, 2017  On April 6-7, 2017, Sequencing.com will ... hackathon at Microsoft,s headquarters in ... focus on developing health and wellness apps that provide ... the Genome is the first hackathon for personal ... largest companies in the genomics, tech and health industries ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... , ... October 12, 2017 , ... ... today announced the three Winners and six Finalists of the 2017 Blavatnik Regional ... by the Blavatnik Family Foundation and administered by the New York Academy of ...
(Date:10/12/2017)... ... October 12, 2017 , ... BioMedGPS announces ... addition of its newest module, US Hemostats & Sealants. , SmartTRAK’s US Market ... hemostats, fibrin sealants, synthetic sealants and biologic sealants used in surgical applications. BioMedGPS ...
(Date:10/11/2017)... ... 11, 2017 , ... At its national board meeting in ... Sheikh, the co-founder, CEO and chief research scientist of Minnesota-based Advanced Space Technology ... in ARCS Alumni Hall of Fame . ASTER Labs is a technology ...
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for ... June 2018 in San Francisco, CA. The Summit brings together current and former FDA ... board directors and government officials from around the world to address key issues in ...
Breaking Biology Technology: